Evidence map›Paper›PMID 26194657›Full record

ArticleDiagnostic pathology2015

Tissue microRNA-126 expression level predicts outcome in human osteosarcoma.

Wei Liu, Zhong-yuan Zhao, Lei Shi, Wen-dan Yuan

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wei LiuCollege of Basic Medicine, Binzhou Medical University, No. 346 Guanhai Road, Laishan District, Yantai, 264003, Shandong, China. binzhou_liuwei@126.com.
Zhong-yuan ZhaoDepartment of orthopedics, Yantaishan Hospital, Yantai, 264000, Shandong, China. bz_zhaozhongyuan@126.com.
Lei ShiCollege of Basic Medicine, Binzhou Medical University, No. 346 Guanhai Road, Laishan District, Yantai, 264003, Shandong, China. bz_shilei@126.com.
Wen-dan YuanCollege of Basic Medicine, Binzhou Medical University, No. 346 Guanhai Road, Laishan District, Yantai, 264003, Shandong, China. bz_yuanwendan@126.com.
Binzhou University · CNYantaishan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNA-126 has been found to be consistently under-expressed in osteosarcoma tissues and cell lines compared with normal bone tissues and normal osteoblast cells, respectively. The purpose of the present study was to detect the expression levels of miR-126 in osteosarcoma patients and to further investigate the clinicopathological, and prognostic value of miR-126.

methodsWe recruited 122 patients with osteosarcomas from the Department of Orthopedic Surgery, Yantaishan Hospital between May 2008 and April 2013. The expression level of miR-126 was determined by qRT-PCR. Associations between miR-126 expression and various clinicopathological characteristics were analyzed using the χ (2) test. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis.

resultsmiR-126 expression was significantly decreased in osteosarcoma tissues compared to adjacent normal bone tissues (2.421 ± 1.250 vs. 6.212 ± 1.843, P = 0.001). We found that low miR-126 expression had significant association with advanced TNM stage (P <0.001), distant metastasis (P <0.001), and higher tumor grade (P = 0.001). Kaplan-Meier survival analysis showed that the miR-126 low-expression group had significantly shorter overall survival time than those with high-expression (log-rank test, P = 0.008). Furthermore, multivariate Cox proportional hazards model analysis showed that miR-126 expression was independently associated with overall survival of patients with osteosarcoma (HR = 3.102, 95 % CI: 1.113-9.023, P = 0.018).

conclusionsThis is the first study revealing that miR-126 down-expression may be related to the prediction of poor prognosis for osteosarcoma patients, suggesting that miR-126 may serve as a prognostic marker for the optimization of clinical treatments.

Indexed as

AdolescentBiomarkers, TumorBone NeoplasmsChinaChi-Square DistributionDown-RegulationFemaleHumansKaplan-Meier EstimateMaleMicroRNAsMultivariate AnalysisNeoplasm GradingNeoplasm StagingOsteosarcomaPredictive Value of TestsBiomarkers, TumorMicroRNAsMIRN126 microRNA, human

Identifiers

PMID26194657
PMCPMC4509614
OpenAlexW1738160483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.